Therefore, because early and better reduction of LDL-C could significantly reduce cardiovascular risk, novel lipid-lowering therapies such as PCSK9-i may be useful to reduce LDL-C levels and thus the vascular burden of FH patients. Here, PCSK9 is linked to familial hyperaldosteronism.